VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib

NCT03400176 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

39

Enrollment

INDUSTRY

Sponsor class

Stopped Business reasons

Conditions

Chronic Lymphocytic Leukemia (CLL)

Interventions

DRUG: VAY736
DRUG: ibrutinib

Sponsor

Novartis Pharmaceuticals